National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-13: The Prospects for Immunizing Against Rotavirus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
318
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

Rodriguez, W.J., H.W.Kim, C.D.Brandt, B.Bise, A.Z.Kapikian, R.M. Chanock, G.Curlin, and R.H.Parrott. 1980. Rotavirus gastroenteritis in the Washington, D.C., area. Am. J. Dis. Child. 134(8):777–779.


Sack, D.A., A.M.A.K.Chowdhury, A.Eusof, M.A.Ali, M.H.Merson, S. Islam, R.E.Black, and K.H.Brown. 1978. Oral hydration in rotavirus diarrhoea: A double blind comparison of sucrose with glucose electrolyte solution. Lancet II:280–283.

Sato, K., Y.Inaba, T.Shinozaki, R.Fujii, and M.Matumoto. 1981. Isolation of human rotavirus in cell cultures: Brief report. Arch. Virol. 69(2):155–160.

Soenarto, Y., T.Sabodo, R.Ridho, H.Alrasjid, J.E.Rohde, H.C.Bugg, G.L.Barnes, and R.F.Bishop. 1981. Acute diarrhea and rotavirus infection in newborn babies and children in Yogyakarta, Indonesia, from June 1978–June 1979. J. Clin. Microbiol. 14:123–129.


Urasawa, T., S.Urasawa, and K.Taniguchi. 1981. Sequential passages of human rotavirus in MA-104 cells. Microbiol. Immunol. 25(10):1025–1035.


Vesikari, T., E.Isolauri, A.Delem, E.O’Hondt, F.E.André, and G.Zissis. 1983. Immunogenicity and safety of live attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet II:807–811.

Vesikari, T., E.Isolauri, E.O’Hondt, A.Delem, F.E.André, and G. Zissis. 1984. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet I:977–981.

Vesikari, T., E.Isolauri, F.E.André, E.d’Hondt, A.Delem, G.Zissis, G.Beards, and T.H.Flewett. 1985. Protection of infants against the human rotavirus diarrhea by the RIT 4237 live attenuated bovine rotavirus vaccine. Pp. 369–372 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A.Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Habor Laboratories.


Wyatt, R.G., C.A.Mebus, R.H.Yolken, A.R.Kalica, H.D.James, A.Z. Kapikian, and R.M.Chanock. 1979. Rotaviral immunity in gnotobiotic calves: Heterologous resistance to human virus induced by bovine virus. Science 203 (4380):548–550.

Wyatt, R.G., K.W.Thiel. L.J.Saif, A.R.Kalica, H.B.Greenberg, A.Z. Kapikian, and R.M.Chanock. 1980. Human rotavirus type 2: Cultivation in vitro. Science 207(4427):189–191.

Wyatt, R.G., H.B.Greenberg, W.D.James, A.L.Pittman, A.R.Kalica, J. Flores, R.M.Chanock, and A.Z.Kapikian. 1982. Definition of human rotavirus serotypes by plaque reduction assay. Infect. Immun. 37 (1):110–115.


Zissis, G., J.P.Lambert, P.Marbehant, D.Marissens, M.Lobmann, P. Charlier, A.Delem, and N.Zygraich. 1983. Protection studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. J. Infect. Dis. 148(6):1061–1068.

Page
318
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)